The Affiliated People's Hospital of Ningbo University
This is a prospective, randomized, two-arm, multicenter, exploratory study aimed at evaluating the efficacy and safety of the combination of etoposide, cytarabine and Pegfilgrastim (EAP regimen) for mobilizing hematopoietic stem cells in patients with newly diagnosed multiple myeloma (NDMM). A total of 99 NDMM patients will be enrolled and randomly assigned to receive either the EAP regimen or the GC regimen (cyclophosphamide+ G-CSF) to mobilize hematopoietic stem cells. Subsequently, the mobilization effects and adverse reactions of all patients will be observed and compared.
Multiple Myeloma
Hematopoietic Stem Cell Mobilization
Etoposide
Cytarabine
Pegfilgrastim
Cyclophosphamide
G-CSF
G-CSF
PHASE3
According to strict inclusion and exclusion criteria, 99 newly diagnosed MM patients will be selected. They will be randomly assigned in a 2:1 ratio to the EAP group or the CG group. During the hematopoietic stem cell mobilization period, comparison study will be conducted regarding the proportion of patients who achieve the ideal collection value (CD34 cells \>5×10\^6/kg) after a single collection; the proportion of patients who cumulatively achieve the target collection value (CD34 cells \>2×10\^6/kg) and the ideal collection value; the cumulative collection of CD34 cells and the average number of collections; and the hematological and non-hematological adverse reactions of the EAP and CG regimens. Special attention will be given to the proportion of patients who add Plerixafor in both regimens.
| Study Type : | INTERVENTIONAL |
| Estimated Enrollment : | 99 participants |
| Masking : | NONE |
| Primary Purpose : | TREATMENT |
| Official Title : | A Prospective, Multicenter, Randomized Controlled Study of Etoposide, Cytarabine Combined With Pegfilgrastim vs. Cyclophosphamide Combined With G-CSF for Hematopoietic Stem Cell Mobilization in Newly Diagnosed Multiple Myeloma Patients |
| Actual Study Start Date : | 2024-08 |
| Estimated Primary Completion Date : | 2026-12 |
| Estimated Study Completion Date : | 2026-12 |
Information not available for Arms and Intervention/treatment
| Ages Eligible for Study: | 18 Years to 75 Years |
| Sexes Eligible for Study: | ALL |
| Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
RECRUITING
Dongyang People's Hospital
Dongyang, Zhejiang, China,
RECRUITING
The First Affiliated Hospital, College of Medicine, Zhejiang University
Hangzhou, Zhejiang, China,
RECRUITING
Tongde Hospital of Zhejiang Province
Hangzhou, Zhejiang, China,
RECRUITING
Huzhou central hospital
huzhou, Zhejiang, China,
RECRUITING
The First Hospital of Jiaxing
Jiaxing, Zhejiang, China,
RECRUITING
Jinhua Municipal Central Hospital
Jinhua, Zhejiang, China,
RECRUITING
Jinhua People's Hospital
Jinhua, Zhejiang, China,
RECRUITING
Lishui Central Hospital
l I Who, Zhejiang, China,
RECRUITING
Ningbo Medical Center Lihuili Hospital
Ningbo, Zhejiang, China,
RECRUITING
The Affiliated People's Hospital of Ningbo University
Ningbo, Zhejiang, China,
RECRUITING
Shaoxing People's Hospital
Shaoxing, Zhejiang, China,
RECRUITING
Shaoxing Second Hospital
Shaoxing, Zhejiang, China,
RECRUITING
Taizhou Central Hospital
Taizhou, Zhejiang, China,
RECRUITING
Taizhou hospital of Zhejiang province
Taizhou, Zhejiang, China,
RECRUITING
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China,
RECRUITING
The Second Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China,